Mark Battle Selected Research

99mTc-NC100668

1/2007	99mTc-NC100668, an agent for imaging venous thromboembolism: The effect of anticoagulant or thrombolytic therapy on the uptake and retention of radioactivity in blood clots in vivo.
7/2006	The in vivo and in vitro metabolic profile of 99mTc-NC100668, a new tracer for imaging venous thromboembolism: identification and biodistribution of the principal radiolabeled metabolite.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Battle Research Topics

Disease

2	Cognitive Dysfunction 01/2022 - 11/2020
2	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 11/2020
2	Venous Thrombosis (Deep-Vein Thrombosis) 04/2007 - 01/2007
2	Thrombosis (Thrombus) 04/2007 - 01/2007
2	Venous Thromboembolism 01/2007 - 07/2006
1	Death (Near-Death Experience) 11/2020
1	Amyloid Plaque 11/2020
1	Neoplasms (Cancer) 01/2016
1	Breast Neoplasms (Breast Cancer) 01/2016
1	Pulmonary Embolism 01/2007
1	Thromboembolism 07/2006

Drug/Important Bio-Agent (IBA)

2	Amyloid (Amyloid Fibrils)IBA 01/2022 - 11/2020
2	99mTc-NC100668IBA 01/2007 - 07/2006
1	florbetapirIBA 11/2020
1	flutemetamolIBA 11/2020
1	Peptides (Polypeptides)IBA 01/2016
1	4-O-carboxymethylascochlorinIBA 01/2016
1	acetyl- Asn- Gln- Glu- Gln- Val- Ser- Pro- Tyr(3- iodo)- Thr- Leu- Leu- Lys- Gly- NC100194IBA 04/2007
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2007
1	AnticoagulantsIBA 01/2007
1	A-factor (Streptomyces)IBA 01/2007
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2007
1	Thrombin FDA Link 01/2007
1	RadiopharmaceuticalsIBA 07/2006
1	seryl-prolineIBA 07/2006
1	lysylglycineIBA 07/2006
1	leucylleucine (Leu-Leu)IBA 07/2006

Therapy/Procedure

1	Thrombolytic Therapy 01/2007